H7N9 Specific Neutra™ Antibody Products

Accelerate Your Research and Development!

Creative Biolabs’ H7N9 Specific Antibody Products provide precise and reliable tools essential for advancing influenza research, diagnostics, and therapeutic development. Our antibodies offer specific recognition of H7N9 viral proteins, enabling accurate detection, characterization, and neutralization studies. Customers can expect highly validated reagents that support diverse applications, from fundamental research into viral pathogenesis to the development of novel antiviral strategies and vaccine candidates.

Contact our team to get an inquiry now!

Introduction of H7N9

Influenza A virus, particularly the H7N9 subtype, represents a significant global health concern due to its zoonotic potential and high fatality rate in humans. H7N9 is an avian influenza virus that has periodically crossed the species barrier to infect humans, leading to severe respiratory illness. The virus is characterized by its hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins, which are crucial for viral entry and release, respectively. The HA protein, specifically the H7 subtype, is a primary target for antibody-mediated immunity and vaccine development.

Fig. 1 The structure of influenza A virus.Distributed under CC BY 4.0, from Wiki, without modification

Studies underscore HA protein's pivotal role in H7N9 pathogenesis. Research has identified conserved HA head domains, including the beta14-centered surface, as vulnerable targets for broadly neutralizing antibodies. For instance, human neutralizing antibodies like H7.HK1 and H7.HK2 have demonstrated potent neutralization of H7N9 and in vivo protection by binding to these conserved lateral patches on the HA head, disrupting loops essential for viral entry. This conserved binding site suggests the potential for broad-spectrum protection against various influenza subtypes, even against antigenically mutated strains. These findings collectively emphasize the importance of specific antibody products in both understanding and combating the H7N9 virus.

Antibodies Against H7N9

H7N9 specific antibodies are indispensable tools for research, diagnostics, and therapeutics, primarily targeting the viral surface glycoproteins Hemagglutinin (HA) and Neuraminidase (NA) due to their critical roles as antigenic determinants and in viral infection.

Fig. 2 The protection mechanisms of neutralizing and non-neutralizing Abs specific for different proteins of the influenza virus.¹

Applications of H7N9 Specific Antibodies:

• Viral Detection & Quantification: Used in diagnostic assays like ELISA and Western Blot, antibodies precisely detect and quantify H7N9 viral antigens, such as the HA protein, in biological samples (e.g., Influenza H7N9 HA Monoclonal Antibody, clone 04).
• Neutralization Assays: Critical for vaccine efficacy and therapeutic development, neutralizing antibodies (e.g., H7.HK1, H7.HK2, E10) bind to viral proteins, primarily HA, to block infection and demonstrate in vivo protection.
• Immunofluorescence & Flow Cytometry: Fluorescently labeled antibodies visualize viral proteins and quantify infected cells, offering insights into viral tropism and pathogenesis.
• Immunohistochemistry (IHC): Antibodies detect H7N9 antigens in tissue samples, aiding viral distribution and pathology studies.
• Antiviral Drug & Vaccine Development: As crucial reagents, H7N9 antibodies screen and validate novel antiviral compounds and vaccine candidates by assessing drug binding to viral targets or measuring vaccine-elicited immune responses.
• Structural Biology Studies: Antibodies binding to specific viral epitopes assist techniques like Cryo-EM to elucidate viral protein structures, providing critical information for rational drug and vaccine design.

Why Choose Us?

Creative Biolabs stands at the forefront of providing high-quality H7N9 specific antibody products, offering unparalleled advantages for your research and development efforts. Our commitment to scientific excellence, rigorous validation processes, and deep understanding of influenza biology set us apart.

• Exceptional Specificity and Sensitivity: Our H7N9 antibodies are meticulously developed and validated to ensure high specificity for H7N9 viral proteins, minimizing off-target binding and maximizing detection sensitivity, crucial for accurate research outcomes.
• Application Versatility: Creative Biolabs' H7N9 antibodies are engineered for diverse applications including ELISA, Western Blot, Immunofluorescence, Flow Cytometry, and in vitro neutralization assays, delivering adaptable solutions for varied research requirements.
• Robust Validation and Quality Control: Every antibody undergoes stringent quality control testing and functional validation, ensuring consistent performance and reproducibility across experiments.
• Expert Scientific Support: Our team of experienced biologists and immunologists provides comprehensive technical support, offering guidance on product selection, experimental design, and troubleshooting to ensure your success.
• Contribution to Universal Flu Solutions: Our focus on highly specific antibodies, including those targeting conserved epitopes, directly contributes to the global effort to develop more effective and universal influenza countermeasures, building on insights from published research on broadly neutralizing antibodies.

FAQs

Here are some common questions from researchers interested in H7N9 specific antibody products:

Access the Creative Biolabs Edge – Request Your Quote Now

REFERENCE

1. Padilla-Quirarte, Herbey O et al. “Protective Antibodies Against Influenza Proteins.” Frontiers in immunology vol. 10 1677. 18 Jul. 2019, DOI:10.3389/fimmu.2019.01677. Distributed under Open Access license CC BY 4.0, without modification.